Alle Storys
Folgen
Keine Story von Intercell AG mehr verpassen.

Intercell AG

euro adhoc: Intercell AG
Joint Ventures/Cooperation/Collaboration
Intercell AG and CSL Ltd. sign Exclusive Agreement for Marketing and Distribution of Japanese Encephalitis Vaccine

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
30.08.2005
Vienna, Austria, August 30, 2005 - Intercell AG announced today the
signature of an exclusive agreement with CSL Ltd. for the Marketing
and Distribution of Intercell´s novel cell culture based Japanese
encephalitis vaccine in Australia. It is Intercell’s first
commercialization agreement for the future delivery of its lead
vaccine product which is planned to enter Phase III clinical trials
in September 2005.
In order to optimally market the vaccine in Australia where the
disease is endemic, Intercell has been seeking for a strong local
strategic partner. Under the terms of this agreement CSL Ltd.
receives the sole and exclusive marketing and distribution rights of
Intercell´s novel prophylactic vaccine against Japanese encephalitis
in Australia, New Zealand, Papua New Guinea and Pacific Islands.
Intercell is planning to market the product independently from this
agreement with CSL Ltd. in the United States and Europe targeting the
travelers and armed forces market to replace current suboptimal
vaccines produced on mouse brain.
The production of the vaccine will be performed at Intercell´s
state-of-the-art vaccine manufacturing facility in Livingston,
Scotland.
"This agreement with the leading vaccine company in Australia is
another important step forward in our global marketing and
commercialization strategy for this modern cell culture based
Japanese Encephalitis vaccine", states Gerd Zettlmeissl, COO
Intercell AG. "It proves our vaccine to be highly attractive for
marketing and distribution and further substantiates our business
strategy to generate significant future revenues through product
sales."
About Intercell’s JE vaccine Intercell´s novel Japanese Encephalitis
vaccine is a purified, inactivated vaccine for active immunization of
adults against the Japanese Encephalitis virus and has successfully
concluded Phase II clinical trials.  In a Phase II head-to-head
comparison with JE-VAX®, Intercell’s vaccine was shown to be: » Less
reactogenic - both in frequency and intensity » More potent - higher
antibody levels at all doses studied one month after   the
immunizations; this vaccine also showed high seroconversion rates one
month after a single dose » More convenient - 2 doses versus 3 doses
and liquid versus freeze-dried   format » More persistent - higher
persistence of antibodies two years after primary   immunization
More detailed Phase II results were presented at the 53rd annual
meeting of the American Society of Tropical Medicine and Hygiene, Nov
7th - Nov 11th 2004 in Miami.
About CSL CSL Limited is a global, specialty biopharmaceutical
company that develops, manufactures and markets products to treat and
prevent serious human medical conditions; Headquartered in Melbourne
Australia, the CSL Group includes CSL Bioplasma, CSL Pharmaceutical
and ZLB Behring incorporating ZLB Plasma Services; CSL has over 7,000
employees working in 25 countries, with major facilities in
Australia, Germany, Switzerland, US and Japan; CSL's Pharmaceutical
Division develops, manufactures and markets vaccines for human use.
The Division markets a comprehensive range of Children’s vaccines,
Travel Vaccines, Respiratory Vaccines Adult Vaccines and Antivenoms;
and, the Division also markets Antibiotics, Dermatological Products,
Emergency Products, Neurological Products, Analgesic Products, and
Urological Products supplied by other manufacturers. For more
information please visit www.csl.com.au
About Intercell  Intercell AG is a fast growing biotechnology company
with a clear strategy and focus on the design and development of
novel vaccines for prophylaxis and treatment of diseases with
substantial unaddressed medical need. The Company’s unique position
is based on the combination of antigens and immunizers (adjuvants)
derived from its proprietary technology platforms and its in-house
GMP manufacturing facilities. Intercell’s technology has been
endorsed by collaborative agreements with a number of global
pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc.,
SciGen Ltd. and the Statens Serum Institut. The Company has a broad
development pipeline with a vaccine for Japanese Encephalitis about
to enter Phase III, a vaccine for Hepatitis C undergoing Phase II
trials, and five products focused on infectious diseases in the
pre-clinical phase. Intercell is listed on the Vienna stock exchange
under the symbol "ICLL". For more information please visit:
www.intercell.com
end of announcement                               euro adhoc 30.08.2005 07:53:19

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN:
Börsen: Wiener Börse AG / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG